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I.

General Introduction
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A.

Renal and Cardiac Transplantation: overview and current challenges

The first successful solid-organ transplantation procedure was performed in Boston,
USA, in 1954. A kidney was transplanted from a healthy donor to his identical twin
suffering from kidney failure.1 Although attempts at organ transplantation had been
carried out decades prior to that, they were unsuccessful.2 Since this first-reported
successful transplantation,1 the field of organ transplantation has witnessed tremendous
advancements in scope, number of procedures and outcome quality. Today, organ
transplantation is considered the treatment of choice for end-stage organ failure. In 2002,
150,000 individuals were living in the US with functioning allografts compared to 62,000
in 1993.3

Despite the great strides that were made in the field of organ transplantation, several
challenges continue to face clinicians, researchers and health care planners alike, as
well as -very importantly- patients. The 1-year renal and cardiac transplant survival (9095% and 87%, respectively) has improved since the dawn of transplantation.
Nevertheless, the 10-year survival rates fall dramatically to 51-68% and 50%,
respectively, with modest improvements over the past two decades.4-6 This is In spite of
lower rates of acute rejection episodes.7 Progressive allograft tissue damage and
deterioration of graft function is observed in all transplanted organs and is collectively
and generically called “chronic allograft dysfunction”. Intervention to effectively prevent
or interrupt this process remains a challenge.8

Another

challenge

is

that

transplant

patients

are

placed

on

long-term

immunosuppression. Clearly, Immunosuppressive drug regimens reduced the rate of
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acute rejection,8 but they have side-effects which could injure the allograft itself9 or
cause an increased susceptibility to infections or malignancy.10 The ultimate goal of
immunosuppression or “immuno-intervention” is to achieve immunologic tolerance;
intervening at an early stage of transplantation, through manipulation of the immune
response, so that the recipient immune system no longer identifies the allograft as
foreign.11 However, trials that tested the impact of withdrawal of immunosuppressant
medication showed deterioration of graft function for the majority of the patients.12, 13

A multitude of medical conditions and co-morbidities complicate the medical care of
transplant recipients and pose another major challenge. One study reported that
approximately 30% of all deaths in renal transplant patients after the first year are due to
cardiovascular complications.14 Infection and malignancies account for 11% and 10%,
respectively, of such deaths.14 Diabetes is highly prevalent in transplant patients (20%)15
and constitutes in itself another risk factor for cardiovascular diseases. Additionally,
immunosuppressive therapy using calcineurin inhibitors and corticosteroids has been
associated with higher incidence of diabetes after transplantation. 16

More than 50 years have passed since the first report of a successful solid-organ
transplantation procedure. Tremendous advancements have taken place in all different
aspects of the transplantation process, which in turn made this treatment option a widely
applied therapy for end-stage organ failure. A host of challenges, however, need to be
overcome to optimize outcomes and reduce risks of this therapeutic modality. The
continued research in the field of organ transplantation and cellular and molecular
biology will hopefully bring us closer to that goal.
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B.

Chronic Allograft Nephropathy (CAN): etiology and mechanisms

Although the term CAN has been used extensively in the literature to describe any
pathologic change that affects the renal allograft, the need to identify specific causes of
CAN and understand the underlying mechanisms of allograft injury has been
emphasized in recent years17, 18. The identification of such mechanisms is necessary to
devise appropriate treatments and interventions for the long-term management of renal
transplant patients.

Chronic damage and injury to renal allografts is mediated by alloimmune-dependent and
alloimmune-independent mechanisms19, 20. One of the major alloimmune-dependent
mechanisms of CAN is chronic rejection17, 18. Chronic rejection manifests as a slowly
progressive cortical scarring of the allograft. This is mainly an antibody-mediated
process as evidenced by the widespread C4d deposits (split product of the complement
system classic pathway, marker of antibody-induced injury21) in the peritubular
capillaries viewed by immunofluorescence microscopy22, 23. Human and animal studies
have shown that donor-specific antibodies were associated with the development of
CAN24, 25. Chronic, T-cell-mediated, allograft arteriopathy is also observed. This is
suggested by the disruption of the lamina elastica interna, inflammatory cells in the
fibrotic intima and proliferation of myofibroblasts in the intima26, 27. It is more likely,
however, that chronic injury is mediated by an interplay of both the humoral and cellular
arms of the immune system28. The role of calcineurin inhibitor (CNI) toxicity as a
contributor to allograft damage has been recognized for several years9, 29.

The exact mechanisms that cause allograft damage are not clearly understood but they
all proceed through inflammatory pathways that involve the activation and upregulation
4

of different cytokines and adhesion molecules. For example, a recent animal study
reported that an interleukin 6 (IL-6) -neutralizing antibody prevented occurrence of
cyclosporine induced nephrotoxicity30.
Other alloimmune-independent risk factors include older donor age31, 32, younger
recipient age32, delayed graft function33 and ischemia-reperfusion injury34.

C.

Periodontitis: association with systemic inflammation

Periodontitis is a chronic inflammation of the tooth-supporting tissues that is caused by
an interplay between a sub-gingival, predominantly gram–negative, bacterial
plaque/biofilm and an overt inflammatory response of a susceptible host 35, 36.
Periodontitis is characterized by progressive loss of the attachment and supporting bone
of the tooth and, if left untreated, leads to eventual tooth loss.

The past decade has witnessed an explosion of information regarding a link between
periodontitis and systemic diseases. Since several epidemiologic studies37, 38 reported a
significant association between periodontal disease and cardiovascular disease (CVD),
the volume of research investigating a role for periodontitis in systemic inflammation and
systemic disease, including stroke39, diabetes mellitus40, pre-term pregnancy41 and endstage renal disease42 has been increasing exponentially.

In a meta-analysis of longitudinal and cross-sectional studies, Bahekar et al43 reported
that patients with periodontitis had a higher risk for developing CVD with a relative risk of
1.14 in prospective studies and odds ratio of 1.59 to 2.2 in case-control and crosssectional studies. A randomized controlled interventional study44 has shown that
5

intensive periodontal treatment improved endothelial function, a surrogate marker for
future atherosclerosis45, and reduced serum E-selectin levels at 2 and 6 months. This
association, however, has not been confirmed in other studies46, 47. Other interventional
studies are ongoing48 and are expected to provide more information on the causality of
the link and/or the benefit from periodontal treatment as measured by true endpoints of
CVD.

A very interesting area of research in this field is to elucidate the mechanisms that
explain the association between periodontitis and systemic inflammation and systemic
diseases. One proposed mechanism is that many systemic diseases (e.g.
atherosclerosis, diabetes mellitus) are in essence either induced or propagated by an
inflammatory process49, 50, and periodontal inflammation contributes incrementally to
systemic inflammatory mediator levels. This would in turn contribute to the worsening or
acceleration of the existing systemic disease. In support of this hypothesis, human
studies reported higher serum C-reactive protein (CRP)51, 52,(IL-6)52, tissue plasminogen
activator (TPA)53, tumor necrosis factor alpha (TNF-α)54, 55 in subjects with periodontal
disease compared to periodontally-healthy subjects. While several studies reported a
reduction of systemic cytokine levels after periodontal treatment54, 56, other studies did
not find significant reductions57, 58. Thus, further interventional studies with long-term
follow-up are required to evaluate the benefit of periodontal treatment in modifying
systemic inflammation and influence on systemic disease experience.

6

II.

Periodontitis and Inflammatory Markers in Transplant Recipients
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A.

Objectives:
1.

General objective:

To investigate whether inflammatory periodontal disease in solid-organ transplant
recipients influences/contributes to systemic inflammatory cytokine levels, which
might in turn affect the clinical course of the allograft.
2.

Specific objectives:

Using a population of stable, solid-organ, transplant patients, and an agematched systemically-healthy control population, we aimed to:
a)

Investigate the prevalence of periodontal disease in a solid-organ transplant
population and compare it to the prevalence of periodontal disease in a
systemically-healthy control population.

b)

Investigate if periodontal disease and different periodontal parameters are
correlated with systemic interleukin 6 (IL-6) and C-reactive protein (CRP),
after adjusting for known predictors/determinants of their systemic levels.

c)

Investigate if IL-6 mRNA levels in gingival tissue from diseased sites are
correlated with systemic levels of IL-6 in solid organ recipients.

8

B.

Introduction:

The link between periodontal inflammation and systemic health has been the focus of
much scientific research in the past few years. This was stimulated by a better
understanding of the role of inflammation in the pathogenesis of periodontitis and certain
systemic diseases49, 59, 60. One proposed pathogenetic mechanism is that excessive
release of inflammatory cytokines in diseased periodontal tissues contributes to the
serum cytokine pool, which promotes systemic disease. Evidence supporting this
hypothesis comes from ex-vivo and clinical studies. Cells within the diseased
periodontium produce significantly higher levels of IL-6 compared to healthy gingival
tissues, and periodontal disease has been linked to higher serum IL-6 in several
studies61, 62. Similarly, serum CRP has been reported to be elevated in patients with
periodontitis63. Perhaps, the most convincing evidence for a causal association between
systemic and periodontal inflammation comes from studies showing that treatment of
periodontitis reduced serum glycated hemoglobin and inflammatory marker levels in
diabetic64 or healthy subjects44.

Solid organ transplantation is the definitive therapeutic approach in patients with endstage organ disease. Kidney and heart are the most commonly transplanted organs, with
more than 17,000 kidney and 2,000 heart transplants performed in the United States in
2008 (http://optn.transplant.hrsa.gov). Despite the high graft survival rates after the first
year post-transplantation (more than 85%), the 10-year graft survival rates decrease
dramatically (less than 55%)65. The main effector mechanism for chronic transplant
deterioration is inflammation which is modulated by alloimmune-dependent and
alloimmune-independent factors. Examples of alloimmune-dependent factors are human
9

leukocyte antigen (HLA) mismatches, panel reactive antibody (PRA) scores and acute
rejection. Alloimmune-independent factors include cold ischemic time,
ischemia/reperfusion injury, smoking, diabetes, and living versus cadaveric donor20, 66.
Clinically, serum and urine IL-6 levels are indicators of acute rejection episodes67, 68 and
successful anti-rejection therapy reduces serum IL-669. Similarly, CRP was shown to be
a predictor of renal allograft survival70.

Given the importance of IL-6 and CRP in transplant deterioration and the link between
periodontitis and these systemic inflammatory markers, we explored whether
periodontitis is a modifier of systemic IL-6 and CRP in solid organ transplant recipients.
Thus, the goals of this study were: a) to assess the periodontal status of organ
transplant recipients and compare it to an age-matched healthy group; b) to assess
serum IL-6 and CRP levels and test a possible association between serum levels and
gingival IL-6 mRNA expression.

C.

Materials & Methods:
1.

Subject recruitment

One hundred and forty-four renal and cardiac transplant recipients were screened during
routine outpatient visits at Hartford Hospital Transplant Center. Inclusion criteria were: 1)
clinically stable (measured by serum creatinine levels and cardiac ejection fraction in
renal and cardiac transplant patients, respectively); 2) at least 1 year post-transplant; 3)
absence of other systemic conditions that might directly affect systemic inflammatory
status e.g. rheumatoid or autoimmune diseases; 3) negative history of antibiotic use
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during the preceding 4 months; and 4) no periodontal treatment within the last year.
Ninety renal and cardiac transplant patients met these criteria.
Recruitment strategy of controls included: 1) broadcast email to University of
Connecticut Health Center (UCHC) employees; 2) Invitation letters mailed to General
Clinical Research Center and Women’s Health Center patients at UCHC; 3)
Advertisements in local newspapers. Seventy-two systemically healthy subjects with no
periodontal treatment within the last year and no history of antibiotic use during the
preceding 4 months were recruited (36 UCHC employees, 16 invitation letter
respondents and 20 newspaper advertisement respondents). The study was approved
by the Institutional Review Boards of UCHC and Hartford Hospital.

2.

Data Collection

Medical information of transplant subjects was extracted from hospital records and
included age, gender, ethnicity, weight, height, diabetic status, smoking history, number
of years since transplant, history of rejection episodes, medication regimen/dosages,
HLA mismatching, PRA score, cadaveric or living donor, related or unrelated donor. A
detailed health review questionnaire was used in the control group which included
questions that might identify an undiagnosed systemic condition (e.g. frequency of
urination, dermatologic lesions).

All subjects received a comprehensive oral examination including opportunistic
infections, caries, missing teeth, plaque index (PI), bleeding on probing (BOP), probing
depth (PD), clinical attachment level (CAL) and gingival overgrowth (GO) according to
Pernu et al71. Advanced periodontitis was defined as at least 2 interproximal sites with
CAL≥6mm (not on the same tooth) plus 1 interproximal site with PD≥5mm72.
11

3.

Blood and Tissue Sampling:

Fifteen ml of venous blood were drawn from all subjects prior to oral examination.
Gingival granulation tissue was collected from transplant patients with advanced
periodontitis (n=19) who received non-surgical periodontal therapy, using a sharp curette
in the deepest pocket. Gingival tissue samples were snap frozen in liquid nitrogen and
stored at -80º C.

4.

Sample analyses:

Within 2 hours of blood collection, sera were separated after clotting for 30 minutes at
4ºC, followed by centrifugation at 3,000 x g for 15 minutes. Aliquots were stored at -80ºC
until testing. Sera were coded and analyzed in duplicate by ELISA 1. The IL-6 and CRP
assay analytical sensitivities were 2.0 pg/ml and <0.3 mg/L, respectively, and the
variation in protein values within runs was <1% for both assays.

Total RNA was extracted from gingival samples 2 and quantitative real-time PCR 3 was
performed using commercially available primers and probes 4 for IL-6. The PCR product

1

Diagnostic Products, Los Angeles, CA.

2

TriZOL, Invitrogen, Carlsbad, CA.

3

TaqMan Universal PCR Master Mix, Applied Biosystems.

4

Applied Biosystems, Bedford, MA.
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was measured in 40 consecutive cycles during each reaction using appropriate
software 5. IL-6 cDNA was normalized using 3 housekeeping genes (GAPDH, actin and
β 2 M) in each sample. Nuclease-free water was used as a negative control in each
reaction.

5.

Statistical Analyses

Means and medians of continuous periodontal variables and percentage of sites with
PD≥5mm or CAL≥4mm were calculated for each subject and group. Considering the
frequency distribution of the values above the threshold of detection, undetectable
serum IL-6 values were recorded as 0.5 pg/ml. Natural logarithm transformation was
applied to non-normally distributed variables. Continuous and dichotomous variables
were compared among groups using a two-sample student t-test or χ2 test, respectively.
Multivariate linear regression analysis determined predictors of serum IL-6 and CRP.
Our transplant group sample size permits detection of an effect size of 0.18 at a p=0.05,
in a multivariate analysis with 6 predictors and β≤0.2. Pearson correlation tested
associations between serum IL-6, CRP and continuous periodontal variables. Partial
correlations test was used to test the association between serum IL-6 and periodontal
tissue IL-6 mRNA levels while controlling for diabetes. p≤0.05 was considered
statistically significant.

5

iCycler iQ PCR detection system software, Bio-Rad.
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D.

Results
1.

Population characteristics and periodontal findings

Population demographics, periodontal and serum findings in transplant and control
groups appear in Table 1 (page 40) and Table 2 (page 42). Controls had slightly more
females, lower body mass index (BMI) and lower percentage of diabetics compared to
the transplant group. Mean PD, percentage of sites with PD ≥5mm, percentage of sites
with CAL≥4mm and number of missing teeth were higher in the transplant group
compared to control. Twenty-one percent of the transplant subjects had advanced
chronic periodontitis compared to 15% of the controls, but the difference was not
statistically significant (p=0.34). Six and a half percent of the transplant group had mild
localized gingival overgrowth (score 1), compared to 0% in the control group.

2.

IL-6, CRP and periodontal status

The transplant group had higher mean serum IL-6 and CRP levels compared to the
control group (Table 1, page 40). Serum IL-6 and CRP levels were positively correlated
with each other, in transplant (r=0.46, p<0.001) and control groups (r=0.35, p=0.003). In
the transplant group, there was no significant correlation between serum IL-6 or CRP
levels and any of the periodontal indices, but the number of missing teeth showed a
positive correlation with serum IL-6 (r=0.29, p=0.006).

Despite the lack of correlation between serum IL-6 and periodontal parameters,
transplant patients with advanced periodontitis had a significantly higher serum IL-6
compared to non-periodontitis transplant subjects (6.0±4.2 pg/ml vs 4.7±4.4 pg/ml,
p=0.04) and there was a trend towards higher serum CRP in this group as well (1.36
14

±1.89 mg/L vs 0.77±1.54 mg/L, p=0.12). Serum protein and gingival mRNA IL-6 levels
were positively correlated in transplant subjects with advanced periodontitis, after
adjusting for diabetes, but correlations were not statistically significant for any of the
housekeeping genes (GAPDH: r=0.32, p=0.17; β 2 M: r=0.28, p=0.23; actin: r=0.27,
p=0.26).

In the control group, serum IL-6 levels were positively correlated with mean PD (r=0.37,
p=0.002), percentage of sites with PD≥5mm (r=0.33, p=0.006) and mean BOP (r=0.38,
p=0.001). Similarly in this group, serum CRP levels were positively correlated with mean
PD (r=0.30, p=0.01) and CAL (r=0.29, p=0.01), whereas the correlation with the
percentage of sites with PD≥5mm approached statistical significance (r=0.23, p=0.06).
Differences in serum markers between advanced periodontitis and non-periodontitis
control subjects did not reach statistical significance (3.7±1.3 pg/ml vs 2.9±1.6 pg/ml,
p=0.06, and 0.38±0.42 vs 0.27±0.38, p=0.38, for IL-6 and CRP, respectively).

3.

Predictors of serum inflammatory markers

In the transplant group, independent predictors of serum markers that were tested in the
multivariate model were age, gender, diabetes (yes/no), smoking status (current/former
vs. never smoker), BMI, years since transplant, immunosuppressant dose (prednisone,
dichotomized at the 75th percentile), cyclosporine (yes/no), tacrolimus (yes/no), history of
rejection (yes/no), living donor (yes/no), HLA mismatches, PRA score, advanced
periodontitis, as well as all continuous periodontal variables. Variables with p value >0.2
were excluded from the model. The final model is shown in Table 3 (page 43) and Table
4 (page 44). Significant predictors of higher serum IL-6 in this group were older age,
diabetes, higher BMI, and cadaveric donor, whereas the number of years post transplant
15

approached statistical significance. In the control group advanced periodontitis, higher
BOP and greater percentage of sites with PD ≥5mm were significant predictors of higher
serum IL-6, whereas BMI approached statistical significance (Table 3, page 43). With
respect to serum CRP levels, diabetes and higher BMI were significant predictors of
higher CRP in the transplant whereas in the control group, only higher BMI was a
significant predictor (Table 4, page 44).

E.

Discussion

The prevalence of advanced chronic periodontitis in our transplant population was higher
than the control group, but the difference was not statistically significant. The statistically
significant differences we observed in certain continuous periodontal variables are
clinically small and not unexpected considering that the transplant group had greater
numbers of diabetics and former or current smokers, both of which are risk factors for
periodontitis 73, 74. Other studies, reported higher 75, 76, similar 77 or lower 78 prevalence of
periodontitis in transplant subjects compared to controls. However, differences in
periodontitis case definitions prohibit a direct comparison between studies.
In this study, periodontitis was defined using the AAP/CDC criteria for severe
periodontitis 72. This definition was chosen for several reasons: First, the definition is
very stringent in its severe disease category, so that true disease can be detected
outside the margin of measurement error. Second, this classification enables the
identification of a population subset with a more pronounced and more readily
identifiable systemic impact of periodontal inflammation 51, 56. Third, the adoption of this
definition by our study and, hopefully, future population-based studies will make the
interpretation and comparison of data more feasible.
16

The transplanted organ constitutes a constant challenge to the host immune system.
Chronic low-grade activation of inflammatory cells results in a cascade of events leading
to elevated systemic inflammatory mediator levels 79, 80. This explains our finding of
elevated levels in circulating IL-6 and CRP in transplant subjects compared to healthy
controls, as shown in earlier reports by our group and others 81, 82

Interestingly, studies have reported that the exact sources of serum IL-6 are unclear and
may originate in tissues other than the transplanted organ 83, 84. While advanced
periodontitis was a significant predictor of serum IL-6 in the control group, it was not a
significant predictor in the transplant group (F=0.06, p=0.8). Significant predictors of
higher IL-6 were older age, diabetes, higher BMI and a cadaveric donor, consistent with
other reports in the literature 85-88.

The lack of significance in the multivariate analysis between periodontal parameters and
inflammatory markers in transplant subjects, which contradicts some of our preliminary
findings 82, could be due to several reasons. A possible explanation is a true lack of
association, given the strong “inflammatory” confounding by diabetes and the constant
allograft-mediated antigenic stimulation in transplant subjects. Another reason could be
that periodontally-driven inflammation is dampened by immunosuppressive therapy,
which is supported by the finding that transplant patients experience limited progression
of periodontitis after initiation of immunosuppression 77.

The positive correlation between serum and gingival IL-6 in transplant patients,
consistent with our preliminary findings 82, is noteworthy. Although only having a trend
17

for statistical significance, this moderate size correlation, considering the small sample
size and possible effects of immunosuppressive treatment on the periodontium,
suggests a possible contribution of periodontal tissue IL-6 to circulating IL-6.
Nevertheless, clinical periodontal indices were not predictive of serum IL-6 in the
transplant population. These seemingly conflicting findings could be reconciled by
acknowledging that periodontitis levels were relatively low in our transplant population,
which might have prohibited finding a significant association with serum IL-6 levels.
Additionally, gingival mRNA levels were only quantified in the deepest pockets of a
transplant subset with advanced periodontitis whereas clinical periodontal indices were
assessed in all patients.

The cross sectional nature of this study prevents the assessment of a cause and effect
relationship between periodontitis and systemic inflammation. Future research should
aim at longitudinal evaluation of periodontal indices and their correlation with systemic
markers of inflammation, as well as the influence of periodontal treatment on local and
systemic markers of inflammation in this population.
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III.

Periodontal Disease, Renal Function and Chronic Allograft
Nephropathy

19

A.

Objectives:
1.

General objectives:

To investigate if clinical and/or histological renal allograft deterioration is associated with
periodontal disease severity, and to determine whether the choice of clinical
determinants of periodontal disease can affect statistical outcomes.
2.

Specific objectives:

Using a population of stable renal transplant patients:
a)

To investigate if deterioration in glomerular filtration rates (GFR) is
associated with periodontal disease severity or various periodontal
parameters.

b)

To investigate if biopsy-proven Chronic Allograft Nephropathy (CAN) is
associated with prevalence of periodontitis, or clinical indices of severity of
periodontitis.

c)

To investigate whether different periodontitis case definitions modify the
resulting associations with GFR changes or biopsy-proven CAN.

20

B.

Introduction:

More than 16,500 kidney transplants were performed during 2008 across the US
(http://optn.transplant.hrsa.gov). Despite greatly improved 1-year survival rates of renal
transplants from living and deceased donors (90 and 95%, respectively), the 10-year
graft survival rates fall dramatically to 46 and 58%, respectively89. In renal transplants,
50–80% of these late failures are attributable to chronic allograft nephropathy (CAN) 89, 90
which is considered the most important cause of renal graft failure after the first year of
transplantation90, 91. CAN is a descriptive term for a number of histologic lesions in renal
transplants characterized by progressive interstitial fibrosis, glomerulopathy, mesangial
matrix increase, vascular fibrous intimal thickening and arteriolar hyaline thickening20.
Clinically, CAN presents as progressive deterioration in renal function, proteinuria, and
occasionally, de novo or secondary hypertension.

Several alloimmune-dependent and alloimmune-independent factors are believed to
influence the development of these histologic changes. Examples of alloimmune factors
include acute rejection episodes, subclinical rejection, HLA mismatching and
allosensitization. Alloimmune-independent factors include graft ischemia, donor age,
cytomegalovirus infection, brain death, calcineurin inhibitors, recipient morbidity,
smoking, diabetes mellitus, age, obesity and hyperlipidemia20. These different
contributing factors are thought to result in transplant endothelial cell injury and
activation, which is considered to be a key event in the pathogenesis of CAN.
Endothelial cell activation triggers a cascade of complex and interdependent events. The
activated endothelium secretes an array of inflammatory cytokines (interleukin 6 (IL-6),
21

interleukin 1 (IL-1), tumor necrosis factor alpha (TNF-α)) leading to progressive
stimulation of other inflammatory cells (e.g. macrophages, T-lymphocytes). This in turn
triggers upregulation of adhesion molecules such as ICAM’s, selectins and MHC
molecules. Thus, leukocyte infiltration is promoted and further cytokine release takes
place from activated inflammatory cells leading to phenotypic switching of key effector
cells (glomerular mesangial cells, fibroblasts, smooth muscle cells). These series of
processes culminate in the accumulation of extracellular matrix proteins in the
interstitium and intima of the vascular endothelium. A vicious circle of sustained
inflammatory reaction from the host’s immune system to the allograft is established, and
leads to progressive graft destruction and loss of function. Interestingly, a heightened
pre-transplant or post-transplant systemic inflammation, as measured by a multitude of
serum cytokines (e.g. C-reactive protein (CRP), vascular adhesion molecule-1,
interleukin 12) has been associated with worse renal allograft outcomes including acute
and chronic rejection70, 92-95.

An oral inflammatory disease that received much attention recently due to a possible link
with systemic inflammation is chronic periodontitis. Chronic periodontitis and consequent
destruction of periodontal tissues is believed to be caused by an interplay between a
sub-gingival, predominantly Gram–negative, bacterial plaque/biofilm and an overt
inflammatory response of a susceptible host35,

36

. Many studies have attempted to

dissect the determinants of host susceptibility to periodontal disease96-99. For example,
epidemiological studies showed that the variability in the level of plaque control within a
population is not always commensurate with disease prevalence100,

101

. Moreover,

molecular analysis of microbial flora revealed a weak positive predictive value for the
presence or absence of specific periodontal pathogens and disease activity100-102.
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Several studies have also shown a hyper-active phagocytic cell phenotype in chronic
periodontitis patients103,

104

, in which excessive production of inflammatory cytokines,

proteases and generation of higher levels of reactive oxygen radicals result in
destruction, as opposed to a protection103, 104. Cumulatively, this evidence indicates that
host susceptibility to periodontitis is related to a hyper-inflammatory phenotype leading
to an exaggerated inflammatory response to microbial challenge and subsequent
untoward destruction of the attachment apparatus.

There is accumulating evidence that links periodontal disease to various systemic
diseases and conditions, including diabetes mellitus40, 105, cardiovascular disease43 and
poor pregnancy outomes106-108. Moreover, higher systemic inflammatory cytokine levels,
such as CRP, IL-6 and E-selectin, have been associated with periodontal disease44, 51, 57,
62, 63

and significant reductions were seen after periodontal treatment44,

54, 109

. These

findings, however, were not confirmed in other studies57, 110-112. Interestingly, a recent
study113 reported that the criteria used to diagnose/define a case of periodontitis has a
significant impact on the resulting associations between periodontitis and pre-term, lowbirth weight pregnancy. The significance of the definition applied to diagnose a case of
periodontitis is also apparent when large epidemiologic studies are compared72, since
some of the observed trends in disease prevalence and related associations are merely
due to different disease thresholds being applied.

Given the evidence that links periodontitis to a hyper-reactive inflammatory phenotype103,
104

and higher systemic inflammatory cytokine levels9,

51, 63

, we hypothesized that

periodontal disease could serve as a marker to identify subjects with a systemic hyperinflammatory phenotype that may consequently be at greater risk for long-term renal
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allograft deterioration. This would have several implications. For example, a history of
periodontitis may identify a population in need of more strict criteria in HLA-matching
before transplantation. This could also necessitate closer monitoring of periodontitissusceptible individuals after renal transplantation for signs of CAN and additional graft
biopsies might be indicated. Finally, in as much as chronic periodontitis can affect
systemic inflammatory cytokine levels, this oral infection could also be causally linked to
CAN, although the cross-sectional nature of our study cannot test this hypothesis. The
aim of this analysis is to investigate the association between the periodontal status of a
cohort of renal transplant patients and renal allograft function and biopsy-proven CAN.
Additionally, considering the reported impact of periodontal disease definition on the
observed associations with systemic disease, we investigated the impact of applying
three different periodontitis case definitions on the observed associations.

C.

Materials and methods:
1.

Subject recruitment

For the purposes of this analysis, a subset of the population described in chapter 2 was
included. This subset was defined by the following criteria: 1) clinically-stable renal
transplant subjects; 2) at least 1 year post-transplant; 3) absence of other systemic
conditions that might directly impact the systemic inflammatory status (e.g., rheumatoid
or autoimmune diseases); 3) negative history of antibiotic use during the preceding 4
months; and 4) no periodontal treatment within the last year; 5) availability of data on the
highest and lowest serum creatinine tests on record, with these tests being at least 6
months apart and at least 6 months after the transplant. Fifty-eight renal transplant
patients who met these criteria were included.
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2.

Data Collection

Medical information of the subjects was extracted from medical records. A standardized
extraction form was used. The extracted data included: patient demographics (age,
gender, ethnicity, weight, and height), co-existing systemic conditions, e.g. diabetes
(yes/no), hypertension (yes/no), smoking status (current, former and never smoker),
number of years since transplant, history of rejection episodes, medication regimen and
dosages, graft survival risk factors (e.g. human leukocyte antigen (HLA) mismatching,
panel reactive antibody (PRA) score, cadaveric or living donor (related or unrelated),
delayed graft function, cold ischemic time, dialysis before transplant, cytomegalovirus
infection), serum creatinine lab results and allograft biopsy reports if available.

Using the highest and lowest serum creatinine values for each subject, GFR values were
estimated using the 4-variable simplified MDRD formula 114 (estimated GFR=186 x
Serum Creatinine -1.154 x Age -0.203 x [1.210 if Black] x [0.742 if Female]). Subjects were
divided into two groups based on whether a deterioration or improvement of GFR
occurred over time (subjects with no change were included in the latter group). In
addition, using the Banff 1997 classification27, the subjects were classified according to
the degree of chronic allograft nephropathy as determined in available biopsy reports.
The criteria for the different categories of this classification are shown in Table 5 (page
45).

Subjects received a comprehensive oral examination. The following parameters were
evaluated and recorded: soft tissue lesions, opportunistic infections commonly
associated with immunosuppression, caries, missing teeth (excluding third molars),
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plaque score (PS), bleeding on probing (BOP), probing depth (PD), clinical attachment
level (CAL) and gingival overgrowth (GO) based on the gingival overgrowth index by
Pernu et al71. Chronic periodontitis was defined using 3 different definitions: the first
definition (DEF1) was 2 or more inter-proximal sites with PD≥5mm or CAL≥4mm (not on
the same tooth). The second definition of chronic periodontitis (DEF2) was 6 or more
inter-proximal sites with PD≥5 or CAL ≥ 4. The third definition of chronic periodontitis
(DEF3) was 2 or more inter-proximal sites in each quadrant with a PD≥5 or CAL ≥ 4.
These definitions were chosen because DEF1 comprises of the moderate and severe
periodontitis categories of the AAP/CDC periodontitis case definition72, and DEF2 and
DEF3 are arbitrary definitions that were devised to represent an escalating extent of
periodontal destruction compared to DEF1.

3.

Blood sampling and analyses:

Fifteen ml of venous blood were withdrawn from all subjects prior to oral examinations.
Serum IL-6 and CRP were measured using enzyme-linked immunosorbent assay.
Techniques were described in detail in chapter I (page 12).

4.

Statistical analyses:

A natural log transformation was applied to non-normally distributed variables. Means
and medians were calculated for continuous variables. Student t-test was used to test for
differences between the groups (GFR deterioration vs. improvement). A multivariate,
repeated measures, linear regression analysis was applied to determine significant
predictors of the within-subject change in GFR values over time. Student t-test was used
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to test for differences of the periodontal variables between the different Banff CAN score
groups. A p value ≤0.05 was considered statistically significant.

D.

Results:

The population demographic and medical data are reported in Table 6 (page 46).
Diabetic patients comprised 52% of the subjects and 53% were former or current
smokers. The median number of years post-transplant was more than 7 years. The
mean time between the two serum creatinine tests was 44.7±43 months with a range of
(6-200) months. 60% of the subjects had a deterioration of estimated GFR levels with a
median value of GFR deterioration of 50 ml/min/1.73 m2 (Table 7, page 47). Serum IL-6
and CRP were not statistically significantly different among the GFR deterioration vs.
improvement/stable groups but there was a trend for higher serum IL-6 and CRP in the
GFR improvement (Table 8, page 48).

Periodontal parameters in the GFR improvement vs. deterioration groups are reported in
Table 9 (page 49). There were no statistically significant differences in mean PD, mean
CAL, percentage of sites with BOP, plaque score, percentage of sites with PD≥5mm,
percentage of sites with CAL≥4mm or the number of missing teeth among the two
groups. The prevalence rates of chronic periodontitis in the GFR improvement vs.
deterioration groups according to the 3 different definitions used are described in Table
10 (page 50). There were no significant differences in the prevalence of periodontitis
between the two groups when DEF 1 and DEF3 were used. However, using DEF2,
chronic periodontitis was more prevalent in the GFR deterioration group and the
difference was statistically significant (Fisher’s exact test, p=0.02) (Table 10, page 50).
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The serum IL-6 and CRP levels in subjects with and without periodontitis according to
the 3 different definitions are shown in Table 11 (page 51). No statistically significant
differences were observed.

A multivariate, repeated measures, linear regression analysis was conducted to
determine significant predictors of the GFR change over time. The variables included
were body-mass index (BMI), diabetes status (yes/no), smoking history (yes/no), living
or cadaveric donor, hypertension, dialysis before transplantation, cold ischemic time,
delayed graft function, acute rejection episodes (yes/no), panel reactive antibody score,
HLA mismatch (less than 3 vs. 3 mismatches or more), cytomegalovirus infection
(yes/no), prednisone use (yes/no), cyclosporine use (yes/no), serum IL-6 and serum
CRP. Continuous periodontal parameters such as mean PD, mean CAL, percentage of
sites with BOP, percentage of sites with PD≥5mm, percentage of sites with CAL≥4mm
and the number of missing teeth were included individually in the model (i.e. they were
not tested simultaneously). Chronic periodontitis, as defined by each definition was
included in the model individually. Variables that returned a p value >0.2 were excluded
from the final model. Accordingly, the following variables were excluded from the final
analysis: BMI, diabetes status (yes/no), smoking history (yes/no), dialysis before
transplantation, cold ischemic time, delayed graft function, panel reactive antibody score,
HLA mismatch (less than 3 vs. 3 mismatches or more, cytomegalovirus infection,
prednisone use (yes/no), cyclosporine use (yes/no), serum IL-6 and serum CRP. The
model which includes the significant medical predictors is shown in Table 12 (page 52).
The direction of change predicted by each of these variables can be deduced by
examining the estimated means of GFR within the categories of each variable, shown in
Table 13 (page 53). GFR change over time (the dependent variable) was statistically
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significant (F=6.12, p=0.02; this represents the impact of time between the two serum
creatinine measurements on GFR levels within the same subject). History of acute
rejection, having a living donor, and being hypertensive statistically significantly
predicted deterioration of renal allograft function. When the continuous periodontal
variables were introduced individually into the model, the percentage of sites with BOP,
mean PD and the percentage of sites with PD≥5mm showed a trend towards statistical
significance in predicting GFR change (Table 14, page 54). To determine the direction of
change predicted by each of these variables (percentage of sites with BOP, mean PD
and the percentage of sites with PD≥5mm), the variables were re-coded into a
trichotomy with cutoff points at the 25th and 75th percentiles. The estimated means of
GFR within the categories of each of these variables are shown in Table 15 (page 55).
Subjects with higher percentage of sites with BOP or PD≥5mm, or a higher mean PD,
had a trend for greater GFR deterioration. Other continuous periodontal variables were
not statistically significant in the model (mean CAL: F=0.06, p=0.81; percentage of sites
with CAL≥4mm: F=0.74, p=0.39; number of missing teeth: F=0.15, p=0.70).

The 3 different periodontitis definitions as were included individually included in the
model. Chronic periodontitis as defined by DEF2 emerged as a statistically significant
predictor of GFR deterioration, while DEF1 and DEF3 were not statistically significant
(F=0.05, p=0.83; F=0.89, p=0.35, respectively). The direction of change predicted by
chronic periodontitis DEF2 can be deduced by examining the estimated means of GFR
in subjects with and without chronic periodontitis, shown in Table 17 (page 58).

Twenty-two subjects had a needle-core biopsy report available. Information regarding
the different time spans between the date of the transplant, date of biopsy, date of the
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GFR measurements and the date of oral exam are shown in Table 18 (page 59). Most of
the subjects had the biopsy taken within one year of the most recent GFR available. One
subject, however, had the biopsy done more than 5 years before the date of the most
recent GFR, which explains the skewed distribution and the large standard deviation
observed. Based on the biopsy report, The BANFF CAN score was deduced for each
subject. Percentage distribution of each score among the 22 subjects is shown in Figure
1 (page 63). Due to the small sample size, the CAN score variable was dichotomized
into a CAN group (Banff CAN scores 1, 2 and 3) vs. no CAN group (Banff CAN score 0).

All 22 subjects that had a biopsy were from the GFR deterioration group. A student t-test
was applied to examine if there were differences in the continuous periodontal variables
(mean PD, mean CAL, percentage of sites with PD≥5mm, percentage of sites with
CAL≥4mm, percentage sites BOP, number of missing teeth) among the two CAN score
groups. There were no statistically significant differences among the two groups for any
of the periodontal variables. A chi square test was used to examine any significant
association between chronic periodontitis history (using the three different definitions)
and the severity of CAN. No significant associations were found for all three definitions
(according to DEF2, all but one subject had chronic periodontitis, which curtails
statistical analysis).

E.

Discussion

This secondary analysis of data was performed on a subset of the renal allograft
recipient population reported in chapter (2). The subjects were included in the analysis if
the available creatinine lab results were taken at least 6 months after the transplantation
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and the two measurements were 6 months apart. Those cutoff points were chosen since
one large study showed that allograft function at 6 months post-transplant, as
measureby creatinine values, and the changes that occurred 6 months later were related
to the 5-year survival of the graft.115 In our study, the GFR values were estimated using
the simplified MDRD formula. The simplified MDRD formula showed comparable
accuracy and correlation to other MDRD formulas in estimating GFR in renal transplant
recipients, and better prediction of true GFR compared to the Cockcrof & Gault
formula.116, 117

Conventionally, graft failure is suspected only when a continued and irreversible fall in
renal function has become clinically apparent, generally, as a combination of
hypertension and proteinuria. Subsequently, renal allograft biopsies are performed to
identify acute graft dysfunction118. Recent studies have indicated that acute rejection
episodes and CAN are often subclinical without any significant impairment of renal
function119-121. These observations have sparked the debate regarding the validity and
benefit of protocol/surveillence biopsies for stable renal allograft patients with the
objective of early intervention in case of graft deterioration118.

The success that has been achieved in improving early survival rates of renal
transplants is still over-shadowed by a significant drop in long-term patient and graft
survival after 10 years.7 Several parameters have been shown to be correlated with
long-term allograft outcomes such as acute rejection episodes,122 the number of human
leukocyte antigen (HLA) mismatches,123 delayed graft function,124 and having a living vs.
a cadaveric donor.125 Nevertheless, these parameters can’t explain the variation in the
clinical course and outcome of organ transplantation.
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A considerable body of research has focused on the role of genetic polymorphism in
organ transplantation126-128. The primary hypothesis of such research is that genotypic
differences lead to different phenotypes of immune responsiveness which is related to
variable inflammatory cytokine, and other inflammatory molecule synthesis. Those
differences are in turn determined by gene polymorphisms. Several cytokine gene
polymorphisms have been examined, including INF-γ129-131, TNF-α131, 132, IL-10130 and IL6133, but associations with graft survival were not conclusive132 and often appeared
contradictory130, 131, 133. Other mediator molecules investigated, with similar inconsistent
findings, include growth factors, e.g. TGF-β130, 132, adhesion molecules (e.g. ICAM)134,
and co-stimulatory molecules (e.g. CCR5)130, 135. Similarly, susceptibility to periodontitis
has been hypothesized to be related to various gene polymorphisms. Researchers have
investigated polymorphisms involving IL-196, 136, IL-698, TNF-α98, 137, vitamin D receptor138,
TLR498, 139 and others140, but the associations with chronic or aggressive periodontitis
were not consistent141, 142. The inconsistent findings are possibly due to the complex
inflammatory-mediator interactions, whereby a single nucleotide polymorphism is
unlikely to explain the spectrum of variation observed in either or both CAN or
periodontitis. Thus, our hypothesis is based on a broad assumption whereby a subjects’
“pro-inflammatory trait/phenotype” is inferred from periodontal disease experience, which
in turn might predict worse long-term allograft outcomes.

In this analysis, we proposed that history of periodontitis indicates a hyper-inflammatory
phenotype, which could in turn cause greater susceptibility to renal allograft deterioration.
This scheme of interaction does not necessarily assume causality, and could be
extended to other areas where a link between periodontitis and various systemic
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diseases is being investigated. In this analysis, periodontal destruction was measured
using a series of continuous variables and 3 different “periodontitis case” definitions. The
decision to include these 3 case definitions was triggered by a recent study113 that
showed that when different disease definitions were applied in the same patient
population, considerably different associations were found when periodontitis and
systemic diseases are investigated.

Sixty percent of our patient cohort experienced a deterioration of GFR function by a
median change of 48 mL/min/1.73m2, while 40% experienced a median improvement of
44 mL/min/1.73m2. These numbers are generally in agreement with observations in
other studies143, 144, with similar populations that compared renal function measures over
time. At least 50% of the patient cohort had the two serum creatinine tests within 2.3
years. The trend toward higher cytokine levels in the GFR improvement group might be
considered counter-intuitive. Interestingly, Muller and colleagues found that a highexpression IL-6 genotype was associated with better graft survival at 3 years. 145

Continuous periodontal variables were not statistically significantly different between the
GFR groups. Clinically-small trends were, however, observed for greater periodontal
destruction and inflammation in the GFR deterioration group as measured by the
percentage of sites with BOP, mean PD and percentage of sites with PD≥5mm. When
the 3 different definitions were used to classify the subjects into periodontally-healthy or diseased subjects, varying prevalence rates were observed. While periodontitis was
more prevalent in the GFR deterioration group compared to the GFR improvement group
according to the 3 definitions, the difference was statistically significant only when using
DEF2. These findings underscore the importance of the “case definition of periodontitis”
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in any study, especially studies investigating a link between periodontitis and systemic
diseases. This is further highlighted by the fact that even when the differences between
the criteria to define disease were small by clinical standards (DEF2 requires 6 proximal
sites with PD≥5 or CAL ≥ 4 while DEF3 requires 8 sites), this was enough to have a
bearing on the statistically significant associations found.

In the multivariate analysis, the demographic and medical variables that were statistically
significantly associated with GFR deterioration were history of acute rejection, having a
living donor, and being hypertensive. Although history of acute rejection146, 147 and
hypertension144 have been shown to be associated with allograft deterioration, renal
allografts from living donors have higher survival rates compared to allografts from
cadaveric donors (http://optn.transplant.hrsa.gov). Our finding of greater renal function
deterioration in subjects with a renal transplant from a living donor could not be
explained by examining the differences in the number of HLA mismatches, percentages
of related and unrelated donors or number of episodes of acute rejection between
transplant patients with a living vs. a cadaveric donor ( Table 19, Table 20 and Table 21;
pages 60-62). Chronic periodontitis as defined by DEF2 was statistically significant in
predicting GFR deterioration. Additionally, the continuous periodontal variables were
introduced individually into the model, higher percentage of sites with BOP, higher mean
PD and higher percentage of sites with PD≥5mm showed a trend towards statistical
significance in predicting deterioration of allograft function (percentage sites BOP:
F=3.27, p=0.08; mean PD: F=3.02, p=0.09; percentage of sites with PD≥5mm: F=2.28,
p=0.14). These findings suggest that periodontal destruction might be a risk indicator for
renal allograft deterioration. Although the analysis of the biopsy report did not yield any
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significant findings, this might be due to the variation in the time period between the
biopsy exam and the oral exam in this study, as well as the small sample size.

Our analysis has several limitations. The GFR values are estimated from two creatinine
measurements that were done at different time intervals for each patient. Also, the most
recent serum creatinine measurement was not done at the same time of the oral
examination. In addition, the single periodontal examination performed in this study does
not permit accurate evaluation of the activity of the disease, although, our hypothesis
addresses the existence of a susceptible phenotype as a risk indicator and not the
causality of the link between active periodontitis and graft deterioration. Another
limitation is that the timing of the biopsy was very variable in relation to the timing of the
creatinine tests available (some biopsies were done before, between or after the
creatinine lab tests). Finally, in the multivariate model, adjusting for medications
introduced bias because patient records reveal that many subjects had frequent
changes to their medication regimen.

In conclusion, although our findings are suggestive of the potential for “periodontitis
susceptibility” to predict renal allograft deterioration, no definitive conclusions can be
drawn. Nevertheless, considering that this was a secondary analysis of cross-sectional
data, and given the small sample size, this study could serve as a pilot study for power
calculations in a future study. A longitudinal study design is necessary that would include
subjects that receive an oral examination pre-transplantation, and whereby serial
creatinine measurements, protocol biopsies and prospective monitoring of allograft
function and periodontal status are conducted. Also, an intervention could be included in
this design in which periodontitis patients would receive intensive periodontal treatment
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pre- or post-transplant. These types of studies could not only support biologically
plausible associations but also can demonstrate causality.
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IV.

Concluding Remarks
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1. Advanced periodontitis was found in 21% of the subjects in a population of stable
renal and cardiac transplant patients. This was not statistically significantly
different from prevalence in a control group (15%).
2. Advanced periodontitis did not emerge as a statistically significant predictor of
serum IL-6 or CRP in renal and cardiac transplant patients after adjusting for
known modifiers of these cytokines.
3. Serum IL-6 was moderately and positively correlated with gingival IL-6 mRNA
expression, although this was a statistical trend only.
4. Periodontal disease and periodontal inflammation, as measured by percentage of
sites with BOP, mean PD and percentage of sites with PD≥5mm, indicated risk
for renal allograft deterioration as measured from estimated GFR values (β=0.25,
0.24, 0.22, respectively) .
5. Periodontal parameters did not correlate with the chronic histologic changes
observed in renal allograft biopsies. This analysis, however, involved only a small
subset of the population.
6. In studies evaluating the association between periodontitis and systemic
diseases or conditions, the criteria used to define a periodontitis case have a
significant influence on the resulting associations.
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Index (tables and figures)
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Table 1: Characteristics of transplant and control groups:
Variable

Transplant group

Control group (n=72)

P value*

(n=90)
Mean±

Median

Mean±

Median

SD

(quartiles)

SD

(quartiles)

Age (years)

53 ± 12

53.5 (44, 61)

51 ± 12

51 (43, 59)

Gender (female) (%)

42%

60%

0.027

Diabetics (%)

56%

3%

<0.001

Smokers (current and

31%

0%

<0.001

0.33(NS)

former) (%)
BMI

PD (mm)

30.2 ±

29.3 (24.5,

27.3 ±

26.2 (24.0,

7.2

33.5)

5.0

30.6)

2.7 ±

2.6 (2.4, 3.0)

2.4 ±

2.4 (2.2, 2.7)

0.001

2.6 (2.3, 3.0)

0.06

0.5
CAL (mm)

2.9 ±

0.007

0.4
2.8 (2.5, 3.2)

0.7

2.7 ±

(NS)

0.6

17.0 ±

11.9 (4.8,

22.0 ±

17.0 (8.7,

0.06

16.7

22.5)

16.7

34.0)

(NS)

46.6 ±

45.9 (19.1,

49.0 ±

53.3 (22.9,

0.60

30.0

71.7)

28.5

73.5)

(NS)

No. of missing teeth

4.2 ±

3 (1, 6)

1.7 ±

1 (0, 3)

<0.001

**

4.9

BOP (%)

PI (%)

2.2
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% Sites with CAL≥

14.4 ±

8.7 (2.8,

9.6 ±

3.8 (0.0,

4mm

16.9

18.7)

13.5

14.3)

% of sites with PD≥

5.2 ±

1.3 (0.0, 8.3)

2.6 ±

0.0 (0.0, 2.6)

5mm

7.9

5.2

Advanced

21%

15%

0.046

0.013

0.34

periodontitis (%)
IL-6 (pg/ml)

5.0 ± 4.3

3.3 (2.4, 5.1)

3.0 ±

2.5 (2.0, 3.7)

<0.000

<0.000

1.6
CRP (mg/L)

0.9 ±

0.30 (0.10,

0.28 ±

0.12 (0.05,

1.63

0.82)

0.39

0.28)

SD: standard deviation, NS: not significant
* t-test or chi square
** 3rd molars excluded
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Table 2: Medical and demographic data of the transplant population
Transplant subjects (n=90)*
Transplant type (kidney)

90%

Ethnicity (black)

32%

Post-transplant years

6.9 ± 4.8, 5.0(3.0, 10.0)

History of acute rejection

36%

Pretransplant dialysis

68%

Living donor (related or

42%

unrelated)
Cyclosporin

24%

Gingival overgrowth

6.0%

Ca++ channel blockers

29%

Prednisone

87%

Mycophenolate

72%

Tacrolimus

54%

Azathioprine

10%

Sirolimus

7%

* Continuous variables shown as mean ± standard deviation, median (quartiles) and
categorical variables reported as percentage frequency
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Table 3: Multivariate linear regression analysis with serum IL-6 as the dependent
variable
Transplant

Variable

F

group*

Control group**

p

β

value
Age

7.93

<0.01

0.30

Diabetes history

6.30

<0.02

0.27

BMI

7.10

<0.01

0.29

Cadaveric donor

6.21

<0.02

0.27

Number of years post-transplant

3.00

0.09

0.19

Number of missing teeth

3.52

0.06

0.21

Variable

F

Gender

p value

β

0.002

0.96

<0.01

Age

0.42

0.52

0.08

Diabetes history

0.20

0.66

0.05

BMI

3.56

0.06

0.24

Advanced periodontitis

6.51

0.01

0.31

10.40

<0.01

0.39

percentage sites with BOP
* r2 = 0.30
** r2 = 0.26
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Table 4: Multivariate linear regression analysis in the transplant group with serum CRP
as the dependent variable

Transplant group*

F

Age

2.31

0.13

0.16

Diabetes_Hx

8.48

0.005

0.30

11.66

0.001

0.35

Advanced periodontitis

1.56

0.22

0.14

Variable

F

Age

0.98

0.33

0.13

Diabetes_Hx

0.81

0.37

0.11

14.23

<0.001

0.43

0.09

0.76

0.04

BMI

Control group*

BMI
Advanced periodontitis
* r2 = 0.23
** r2 = 0.21
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p value

β

Variable

p value

β

Table 5: Banff 97 Classification of Chronic Allograft Nephropathy in Biopsies

Chronic Allograft Nephropathy
Grade

Histopathological findings

1 (mild)

Mild interstitial fibrosis and tubular atrophy without or with specific
changes suggesting chronic rejection

2 (moderate)

Moderate interstitial fibrosis and tubular atrophy

3 (severe)

Severe interstitial fibrosis and tubular atrophy and tubular loss
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Table 6: Demographic and Medical Characteristics

Variable

Mean ± sd (frequency)

Median

Age

52.8±12.0

53.3

Gender (female) (%)

41%

Race (black)

24%

Diabetics (%)

52%

Smokers (current and former)

31%

(%)
Yrs after transplant

7.6±4.9 (n=58)

History of acute rejection

33%

Pre-transplant dialysis

78%

Living donor (related or
43%
unrelated)
Ca++ channel blockers

28%

Cyclosporin

38%

Prednisone

91%

Mycophenolate

72%

Tacrolimus

57%

Azathioprine

21%

Sirolimus

14%

46

7.1 (3.8, 11.0)

Table 7: Estimated GFR Measurement Time Intervals and GFR Change:

Variable

Mean ± SD (frequency)

Median (quartiles)

Months between two GFR tests

44.7±43.1

Range (6-200)
Median 28.5
(13.8, 64.7)

Months between oral exam and

26.7±24.4

recent GFR

Range (2-123)
median 16.7
(11.3, 34.2)

GFR deterioration (% subjects)

60%

GFR Deterioration (mL/min/1.73

56

48 (66, 36)

m2)
GFR improvement (% subjects)

40%

GFR Improvement (mL/min/1.73

44

44 (26, 56)

m2)
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Table 8: Serum IL-6 and CRP cytokine levels in the GFR groups:
GFR improvement

GFR deterioration

group (mean ± SD)

group (mean ± SD)

IL-6 (pg/ml)

5.9 ± 2.0

4.1 ± 1.8

p=0.06

CRP (mg/L)

0.92 ± 2.10

0.44 ± 1.50

p=0.11

* Student t test
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p-value *

Table 9: Continuous Periodontal Variables in the GFR Groups:

Variable

Mean PD (mm)

GFR deterioration

GFR improvement

P

Mean±SD Median

Mean±SD Median (25th,

value*

2.8 ± 0.4

(25th, 75th

75th

quartiles)

quartiles)

2.7 (2.4,

2.6 ± 0.5

2.6 (2.4, 3.0)

3.2)
Mean CAL (mm)

3.0 ± 0.8

2.8 (2.5,

(NS)
2.9 ± 0.7

2.7 (2.4, 3.4)

3.3)
BOP (% of sites)

PI (% of sites)

0.25

0.72
(NS)

18.8 ±

15.0 (6.5,

14.7 ±

7.7 (4.6,

0.14

15.5

25.0)

13.8

28.5)

(NS)

50.7 ±

53.6

43.0 ±

42.4 (10.7,

0.35

29.0

(28.3,

33.0

74.4)

(NS)

4.5 ± 4.5

4.0 (0.0, 8.0)

0.29

76.9)
No. of missing teeth **

2.6 ± 2.6

2.0 (1.0,
4.0)

Sites with CAL≥4mm (%)

Sites with PD≥5mm (%)

(NS)

16.6 ±

9.1 (3.1,

14.9 ±

3.0 (1.8,

0.30

20.1

19.2)

19.8

20.8)

(NS)

7.0 ± 9.2

2.4 (0.0,

5.6 ± 9.0

0.0 (0.0,

0.22

11.4)

(NS)

12.3)
** excluding 3rd molars
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Table 10: Prevalence of Chronic Periodontitis in the GFR Groups:

Chronic periodontitis

GFR deterioration

GFR improvement

P value

DEF 1

94%

87%

p=0.44 * (NS)

DEF 2

91%

70%

p= 0.04 *

DEF 3

57%

39%

p=0.18 ** (NS)

(prevalence in each group)

* Fisher’s exact test
** Chi square test
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Table 11: Serum IL-6 and CRP in periodontitis vs. non-periodontitis subjects (mean ±
standard deviation)
DEF1
CP*

No CP

p value

Serum IL-6

5.1 ± 1.9

4.6 ± 1.9

0.76

Serum CRP

0.60 ± 1.8

0.45 ± 1.5

0.66

CP

No CP

p value

Serum IL-6

4.7 ± 1.9

4.3 ± 1.7

0.70

Serum CRP

0.68 ± 1.85

0.36 ± 1.34

0.11

CP

No CP

p value

Serum IL-6

4.6 ± 1.8

4.7 ± 2.0

0.90

Serum CRP

0.60 ± 1.7

0.60 ± 1.8

0.75

DEF2

DEF3

* CP: chronic periodontitis
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Table 12: Multivariate, repeated measures, linear regression* with GFR change over
time as the dependent variable (statistically significant medical variables):
F

p value

GFR change over time (dependent variable) 6.23

Independent variables

F

p value

.016

β

Partial eta

Observed

squared

Power

History of acute rejection

4.80

.033

0.30

0.09

0.58

Living vs cadaveric donor

6.53

.014

0.34

0.12

0.71

Hypertension

4.01

.051

0.28

0.08

0.50

* n=53
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Table 13: Estimated means of first (older) and second (recent) GFR within the
categories of the significant variables:

GFR (Mean ± SD*) (ml/min/1.73m2)

Variable

No History of Acute rejection

History of Acute rejection

Cadaveric donor

Living donor

Non-hypertension

Hypertension

Time 1**

57.9 ± 34.6

Time 2**

66.4 ± 33.7

Time 1

84.5 ± 56.6

Time 2

45.4 ± 25.8

Time 1

53.7 ± 30.3

Time 2

70.3 ± 36.8

Time 1

88.8 ± 54.6

Time 2

41.5 ± 21.6

Time 1

61.0 ± 38.1

Time 2

66.2 ± 42.0

Time 1

81.5 ± 43.9

Time 2

45.6 ± 27.1

* SD: standard deviation
** Time 1& Time 2: refers to the first and second serum creatinine measurement on
record, respectively, regardless of whether it’s the highest or lowest value on record.
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Table 14: Multivariate, repeated measures, linear regression with GFR change over time
as the dependent variable (Including the statistically significant medical variables and
individual continuous periodontal variables):

P
Independent variables

F

β

value

Partial Eta
Observed Power
squared

History of acute rejection

4.80

.033

0.30

0.09

0.58

Living vs cadaveric donor

6.53

.014

0.34

0.12

0.71

Hypertension

4.01

.051

0.28

0.08

0.50

Percentage of sites with BOP

3.27

0.08

0.25

0.06

0.43

Mean PD

3.02

0.09

0.24

0.06

0.40

Percentage of sites with

2.28

0.14

0.22

0.05

0.32

PD≥5mm
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Table 15: Estimated means of first (older) and second (recent) GFR within the
categories of each periodontal variable: percentage of sites with BOP, mean PD and
percentage of sites with PD≥5mm:

GFR (Mean ± SD*) (ml/min/1.73m2)

Variable

Percentage of sites with BOP (0% - <5%)

(5% – 25%)

(>25%)

Percentage of sites with

(0%)

PD≥5mm
(1 – 10%)

(>10%)

Mean PD

(0.0 - 2.4)

(>2.4 - 3.1)
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Time 1**

69.6 ± 37.9

Time 2**

67.8 ± 46.4

Time 1

72.0 ± 47.2

Time 2

45.5 ± 26.8

Time 1

67.1 ± 38.9

Time 2

55.0 ± 20.3

Time 1

60.9 ± 35.0

Time 2

60.2 ± 38.5

Time 1

75.1 ± 54.6

Time 2

47.1 ± 26.7

Time 1

77.1 ± 31.7

Time 2

48.1 ± 24.8

Time 1

60.7 ± 38.8

Time 2

64.2 ± 41.2

Time 1

71.5 ± 50.4

(>3.1)

Time 2

48.7 ± 29.4

Time 1

79.3 ± 32.2

Time 2

45.8 ± 22.5

* SD: standard deviation
** Time 1& Time 2: refers to the first and second serum creatinine measurement on
record, respectively, regardless of whether it’s the highest or lowest value on record.
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Table 16: Multivariate, repeated measures, linear regression with GFR change over time
as the dependent variable (including the statistically significant medical variables and
chronic periodontitis DEF2):

P
Independent variables

F

β

value

Partial Eta
Observed Power
squared

History of acute rejection

5.14

0.03

0.31

0.09

0.60

Living vs cadaveric donor

7.00

0.01

0.36

0.12

0.74

Hypertension

4.29

0.04

0.29

0.08

0.53

Chronic periodontitis DEF2

4.51

0.04

0.29

0.08

0.55
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Table 17: Estimated means of first (older) and second (recent) GFR within the
categories of Periodontitis DEF2 variable:

GFR (Mean ± SD*) (ml/min/1.73m2)

Variable

Chronic periodontitis

No periodontitis

(DEF2)
periodontitis

Time 1**

59.1 ± 24.9

Time 2**

77.9 ± 48.4

Time 1

72.9 ± 44.7

Time 2

46.8 ± 22.1

* SD: standard deviation
** Time 1& Time 2: refers to the first and second serum creatinine measurement on
record, respectively, regardless of whether it’s the highest or lowest value on record.
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Table 18: Renal Biopsy Time Variables:

Time between transplant

Mean ±SD

Median (quartiles)

66.1 ± 55.0

52.2 (21.4, 95.0)

-2.22 ± 11.6

0.07 (-0.14, 0.20)

1.9 ± 1.4

1.3 (0.8, 2.9)

and biopsy (months)
Time between biopsy and
most recent GFR (months)
Time between biopsy and
oral exam (years)
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Table 19: Frequency distribution of cadaveric, living related and living unrelated donors

Donor type

Frequency

Percentage

Cadaveric

32

56%

Living related

14

25%

Living unrelated

11

19%

Total

57

100%
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Table 20: Cross-tabulation of donor type vs. history of acute rejection:

History_of_acute_rejection

Donor
type

1
13

Percentage within donor type
group

55.2%

44.8%

100.0%

Percentage within history of
acute rejection group

45.7%

68.4%

53.7%

29.6%

24.1%

53.7%

19

6

25

Percentage with donor type
group

76.0%

24.0%

100.0%

Percentage within history of
acute rejection group

54.3%

31.6%

46.3%

35.2%

11.1%

46.3%

35

19

54

64.8%

35.2%

100.0%

Frequency

Cadaveric

Percentage of Total
Frequency

Living

Total

0
16

Percentage of Total
Count
Percentage within donor type group

- Chi square (p=0.11)
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29

Table 21: Cross-tabulation of donor type vs. number of HLA mismatches:

Number of HLA mismatches

Donor
type

3 or more
19

Percentage within donor type
group

9.5%

90.5%

100.0%

Percentage within HLA
mismatches group

40.0%

59.4%

56.8%

5.4%

51.4%

56.8%

3

13

16

Percentage with donor type
group

18.8%

81.2%

100.0%

Percentage within HLA
mismatches group

60.0%

40.6%

43.2%

8.1%

35.1%

43.2%

35

5

32

64.8%

13.5%

86.5%

Frequency

Cadaveric

Percentage of Total
Frequency

Living

Total

Less than 3
2

Percentage of Total
Count
Percentage within donor type group

- Fisher’s exact (p=0.42)
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21

Figure 1: Percentage Distribution of CAN According to the Banff 97 Classification

63

VI.

1.

Bibliography

Merrill JP, Murray JE, Harrison JH, Guild WR. Successful homotransplantation of
the human kidney between identical twins. J Am Med Assoc 1956;160(4):277-82.

2.

Morris PJ. Transplantation--a medical miracle of the 20th century. N Engl J Med
2004;351(26):2678-80.

3.

Sayegh MH, Carpenter CB. Transplantation 50 Years Later -- Progress,
Challenges, and Promises. N Engl J Med 2004;351(26):2761-66.

4.

Cecka JM. The UNOS Renal Transplant Registry. Clin Transpl 2002:1-20.

5.

Taylor DO, Edwards LB, Boucek MM, Trulock EP, Waltz DA, Keck BM, et al.
Registry of the International Society for Heart and Lung Transplantation: twentythird official adult heart transplantation report--2006. J Heart Lung Transplant
2006;25(8):869-79.

6.

Ozduran V, Yamani MH, Chuang HH, Sipahi I, Cook DJ, Sendrey D, et al.
Survival beyond 10 years following heart transplantation: The Cleveland Clinic
Foundation experience. Transplant Proc 2005;37(10):4509-12.

7.

Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in
renal allograft survival despite a marked decrease in acute rejection rates over
the most recent era. Am J Transplant 2004;4(3):378-83.

8.

Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to
improve long-term outcomes after renal transplantation. N Engl J Med
2002;346(8):580-90.

9.

Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD.
Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology.
Transplantation 2004;78(4):557-65.
64

10.

Sheil AGR, Disney APS, Mathew TH, Livingston BER, Keogh AM. Lymphoma
incidence, cyclosporine, and the evolution and major impact of malignancy
following organ transplantation. Transplantation Proceedings 1997;29(1-2):82527.

11.

Salama AD, Remuzzi G, Harmon WE, Sayegh MH. Challenges to achieving
clinical transplantation tolerance. J Clin Invest 2001;108(7):943-8.

12.

Ratcliffe PJ, Dudley CRK, Higgins RM, Firth JD, Smith B, Morris PJ. Randomised
controlled trial of steroid withdrawal in renal transplant recipients receiving triple
immunosuppression. The Lancet 1996;348(9028):643-48.

13.

Srinivas TR, Meier-Kriesche H-U. Minimizing Immunosuppression, an Alternative
Approach to Reducing Side Effects: Objectives and Interim Result. Clin J Am Soc
Nephrol 2008;3(Supplement_2):S101-16.

14.

Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk
factor for cardiovascular death after renal transplantation. Transplantation
2003;75(8):1291-5.

15.

Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney
transplantation in the United States. Am J Transplant 2003;3(2):178-85.

16.

Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM. Post-transplant
diabetes mellitus: increasing incidence in renal allograft recipients transplanted in
recent years. Kidney Int 2001;59(2):732-7.

17.

Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, et al. Banff '05
Meeting Report: differential diagnosis of chronic allograft injury and elimination of
chronic allograft nephropathy ('CAN'). Am J Transplant 2007;7(3):518-26.

18.

Najafian B, Kasiske BL. Chronic allograft nephropathy. Curr Opin Nephrol
Hypertens 2008;17(2):149-55.
65

19.

Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The
natural history of chronic allograft nephropathy. N Engl J Med
2003;349(24):2326-33.

20.

Yates PJ, Nicholson ML. The aetiology and pathogenesis of chronic allograft
nephropathy. Transpl Immunol 2006;16(3-4):148-57.

21.

Bohmig GA, Exner M, Habicht A, Schillinger M, Lang U, Kletzmayr J, et al.
Capillary C4d deposition in kidney allografts: a specific marker of alloantibodydependent graft injury. J Am Soc Nephrol 2002;13(4):1091-9.

22.

Mauiyyedi S, Pelle PD, Saidman S, Collins AB, Pascual M, Tolkoff-Rubin NE, et
al. Chronic humoral rejection: identification of antibody-mediated chronic renal
allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol
2001;12(3):574-82.

23.

Sijpkens YW, Joosten SA, Wong MC, Dekker FW, Benediktsson H, Bajema IM,
et al. Immunologic risk factors and glomerular C4d deposits in chronic transplant
glomerulopathy. Kidney Int 2004;65(6):2409-18.

24.

Poggio ED, Clemente M, Riley J, Roddy M, Greenspan NS, Dejelo C, et al.
Alloreactivity in renal transplant recipients with and without chronic allograft
nephropathy. J Am Soc Nephrol 2004;15(7):1952-60.

25.

Uehara S, Chase CM, Cornell LD, Madsen JC, Russell PS, Colvin RB. Chronic
cardiac transplant arteriopathy in mice: relationship of alloantibody, C4d
deposition and neointimal fibrosis. Am J Transplant 2007;7(1):57-65.

26.

Mihatsch MJ, Ryffel B, Gudat F. Morphological criteria of chronic rejection:
differential diagnosis, including cyclosporine nephropathy. Transplant Proc
1993;25(2):2031-7.

66

27.

Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, et al. The
Banff 97 working classification of renal allograft pathology. Kidney Int
1999;55(2):713-23.

28.

Cornell LD, Smith RN, Colvin RB. Kidney Transplantation: Mechanisms of
Rejection and Acceptance. Annual Review of Pathology: Mechanisms of Disease
2008;3(1):189-220.

29.

Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR.
Natural history, risk factors, and impact of subclinical rejection in kidney
transplantation. Transplantation 2004;78(2):242-9.

30.

LaSpina M, Tripathi S, Gatto LA, Bruch D, Maier KG, Kittur DS. An Interleukin-6Neutralizing Antibody Prevents Cyclosporine-Induced Nephrotoxicity in Mice.
Journal of Surgical Research 2008;148(2):121-25.

31.

Nickerson P, Jeffery J, Gough J, McKenna R, Grimm P, Cheang M, et al.
Identification of clinical and histopathologic risk factors for diminished renal
function 2 years posttransplant. J Am Soc Nephrol 1998;9(3):482-7.

32.

Yilmaz S, McLaughlin K, Paavonen T, Taskinen E, Monroy M, Aavik E, et al.
Clinical predictors of renal allograft histopathology: a comparative study of singlelesion histology versus a composite, quantitative scoring system. Transplantation
2007;83(6):671-6.

33.

Humar A, Johnson EM, Payne WD, Wrenshall L, Sutherland DE, Najarian JS, et
al. Effect of initial slow graft function on renal allograft rejection and survival. Clin
Transplant 1997;11(6):623-7.

34.

Weight SC, Bell PR, Nicholson ML. Renal ischaemia--reperfusion injury. Br J
Surg 1996;83(2):162-70.

67

35.

Schenkein HA. Host responses in maintaining periodontal health and determining
periodontal disease. Periodontol 2000 2006;40:77-93.

36.

Nishihara T, Koseki T. Microbial etiology of periodontitis. Periodontol 2000
2004;36:14-26.

37.

Mattila KJ, Nieminen MS, Valtonen VV, Rasi VP, Kesaniemi YA, Syrjala SL, et al.
Association between dental health and acute myocardial infarction. BMJ
1989;298(6676):779-81.

38.

DeStefano F, Anda RF, Kahn HS, Williamson DF, Russell CM. Dental disease
and risk of coronary heart disease and mortality. BMJ 1993;306(6879):688-91.

39.

Desvarieux M, Demmer RT, Rundek T, Boden-Albala B, Jacobs DR, Jr.,
Papapanou PN, et al. Relationship Between Periodontal Disease, Tooth Loss,
and Carotid Artery Plaque: The Oral Infections and Vascular Disease
Epidemiology Study (INVEST). Stroke 2003;34(9):2120-25.

40.

Lamster IB, Lalla E. Periodontal disease and diabetes mellitus: discussion,
conclusions, and recommendations. Ann Periodontol 2001;6(1):146-9.

41.

Offenbacher S, Lieff S, Boggess KA, Murtha AP, Madianos PN, Champagne CM,
et al. Maternal periodontitis and prematurity. Part I: Obstetric outcome of
prematurity and growth restriction. Ann Periodontol 2001;6(1):164-74.

42.

Kshirsagar AV, Craig RG, Moss KL, Beck JD, Offenbacher S, Kotanko P, et al.
Periodontal disease adversely affects the survival of patients with end-stage
renal disease. Kidney Int 2009;75(7):746-51.

43.

Bahekar AA, Singh S, Saha S, Molnar J, Arora R. The prevalence and incidence
of coronary heart disease is significantly increased in periodontitis: a metaanalysis. Am Heart J 2007;154(5):830-7.

68

44.

Tonetti MS, D'Aiuto F, Nibali L, Donald A, Storry C, Parkar M, et al. Treatment of
periodontitis and endothelial function. N Engl J Med 2007;356(9):911-20.

45.

Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical
cardiologist. Circulation 2002;105(5):546-9.

46.

Hujoel PP, Drangsholt M, Spiekerman C, DeRouen TA. Periodontal disease and
coronary heart disease risk. JAMA 2000;284(11):1406-10.

47.

Beck JD, Eke P, Heiss G, Madianos P, Couper D, Lin D, et al. Periodontal
disease and coronary heart disease: a reappraisal of the exposure. Circulation
2005;112(1):19-24.

48.

Tonetti MS. Periodontitis and risk for atherosclerosis: an update on intervention
trials. J Clin Periodontol 2009;36 Suppl 10:15-9.

49.

Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med
1999;340(2):115-26.

50.

King GL. The role of inflammatory cytokines in diabetes and its complications. J
Periodontol 2008;79(8 Suppl):1527-34.

51.

Noack B, Genco RJ, Trevisan M, Grossi S, Zambon JJ, De Nardin E. Periodontal
infections contribute to elevated systemic C-reactive protein level. J Periodontol
2001;72(9):1221-7.

52.

Loos BG, Craandijk J, Hoek FJ, Wertheim-van Dillen PM, van der Velden U.
Elevation of systemic markers related to cardiovascular diseases in the
peripheral blood of periodontitis patients. J Periodontol 2000;71(10):1528-34.

53.

Taylor BA, Tofler GH, Carey HM, Morel-Kopp MC, Philcox S, Carter TR, et al.
Full-mouth tooth extraction lowers systemic inflammatory and thrombotic markers
of cardiovascular risk. J Dent Res 2006;85(1):74-8.

69

54.

Iwamoto Y, Nishimura F, Soga Y, Takeuchi K, Kurihara M, Takashiba S, et al.
Antimicrobial periodontal treatment decreases serum C-reactive protein, tumor
necrosis factor-alpha, but not adiponectin levels in patients with chronic
periodontitis. J Periodontol 2003;74(8):1231-6.

55.

Iwamoto Y, Nishimura F, Nakagawa M, Sugimoto H, Shikata K, Makino H, et al.
The effect of antimicrobial periodontal treatment on circulating tumor necrosis
factor-alpha and glycated hemoglobin level in patients with type 2 diabetes. J
Periodontol 2001;72(6):774-8.

56.

D'Aiuto F, Nibali L, Parkar M, Suvan J, Tonetti MS. Short-term effects of intensive
periodontal therapy on serum inflammatory markers and cholesterol. J Dent Res
2005;84(3):269-73.

57.

Ioannidou E, Malekzadeh T, Dongari-Bagtzoglou A. Effect of periodontal
treatment on serum C-reactive protein levels: a systematic review and metaanalysis. J Periodontol 2006;77(10):1635-42.

58.

Yamazaki K, Honda T, Oda T, Ueki-Maruyama K, Nakajima T, Yoshie H, et al.
Effect of periodontal treatment on the C-reactive protein and proinflammatory
cytokine levels in Japanese periodontitis patients. J Periodontal Res
2005;40(1):53-8.

59.

Kinane DF, Lappin DF. Immune processes in periodontal disease: a review. Ann
Periodontol 2002;7(1):62-71.

60.

Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin
Invest 2006;116(7):1793-801.

61.

Dongari-Bagtzoglou AI, Ebersole JL. Increased presence of interleukin-6 (IL-6)
and IL-8 secreting fibroblast subpopulations in adult periodontitis. J Periodontol
1998;69(8):899-910.
70

62.

Takahashi K, Takashiba S, Nagai A, Takigawa M, Myoukai F, Kurihara H, et al.
Assessment of interleukin-6 in the pathogenesis of periodontal disease. J
Periodontol 1994;65(2):147-53.

63.

Paraskevas S, Huizinga JD, Loos BG. A systematic review and meta-analyses
on C-reactive protein in relation to periodontitis. J Clin Periodontol
2008;35(4):277-90.

64.

O'Connell PA, Taba M, Nomizo A, Foss Freitas MC, Suaid FA, Uyemura SA, et
al. Effects of periodontal therapy on glycemic control and inflammatory markers.
J Periodontol 2008;79(5):774-83.

65.

2007 Annual Report of the U.S. Organ Procurement and Transplantation
Network and the Scientific Registry of Transplant Recipients: Transplant Data
1997-2006. Health Resources and Services Administration HS. Available
at www.optn.org. Accessed on Dec. 17th, 2008.

66.

Ramzy D, Rao V, Brahm J, Miriuka S, Delgado D, Ross HJ. Cardiac allograft
vasculopathy: a review. Can J Surg 2005;48(4):319-27.

67.

Hartono C, Dadhania D, Suthanthiran M. Noninvasive diagnosis of acute
rejection of solid organ transplants. Front Biosci 2004;9:145-53.

68.

Raasveld MH, Bloemena E, Wilmink JM, Surachno S, Schellekens PT, ten Berge
RJ. Interleukin-6 and neopterin in renal transplant recipients: a longitudinal study.
Transpl Int 1993;6(2):89-94.

69.

Van Oers MH, Van der Heyden AA, Aarden LA. Interleukin 6 (IL-6) in serum and
urine of renal transplant recipients. Clin Exp Immunol 1988;71(2):314-9.

70.

van Ree RM, Oterdoom LH, de Vries AP, Gansevoort RT, van der Heide JJ, van
Son WJ, et al. Elevated levels of C-reactive protein independently predict

71

accelerated deterioration of graft function in renal transplant recipients. Nephrol
Dial Transplant 2007;22(1):246-53.
71.

Pernu HE, Pernu LM, Huttunen KR, Nieminen PA, Knuuttila ML. Gingival
overgrowth among renal transplant recipients related to immunosuppressive
medication and possible local background factors. J Periodontol 1992;63(6):54853.

72.

Page RC, Eke PI. Case definitions for use in population-based surveillance of
periodontitis. J Periodontol 2007;78(7 Suppl):1387-99.

73.

Papapanou PN. Periodontal diseases: epidemiology. Ann Periodontol
1996;1(1):1-36.

74.

Tomar SL, Asma S. Smoking-attributable periodontitis in the United States:
findings from NHANES III. National Health and Nutrition Examination Survey. J
Periodontol 2000;71(5):743-51.

75.

Leung WK, Yau JY, Jin LJ, Chan AW, Chu FC, Tsang CS, et al. Subgingival
microbiota of renal transplant recipients. Oral Microbiol Immunol 2003;18(1):3744.

76.

Lessem J, Drisko C, Greenwell H, Persson R, Newman H, Smart G, et al. Are
cardiac transplant patients more likely to have periodontitis? A case record study.
J Int Acad Periodontol 2002;4(3):95-100.

77.

Oshrain HI, Telsey B, Mandel ID. A longitudinal study of periodontal disease in
patients with reduced immunocapacity. J Periodontol 1983;54(3):151-4.

78.

Rahman MM, Caglayan F, Rahman B. Periodontal health parameters in patients
with chronic renal failure and renal transplants receiving immunosuppressive
therapy. J Nihon Univ Sch Dent 1992;34(4):265-72.

72

79.

Allan JS, Madsen JC. Recent advances in the immunology of chronic rejection.
Curr Opin Nephrol Hypertens 2002;11(3):315-21.

80.

Nocera A, Tagliamacco A, De Palma R, Del Galdo F, Ferrante A, Fontana I, et al.
Cytokine mRNA expression in chronically rejected human renal allografts. Clin
Transplant 2004;18(5):564-70.

81.

Cottone S, Palermo A, Vaccaro F, Raspanti F, Buscemi B, Incalcaterra F, et al.
In Renal Transplanted Patients Inflammation and Oxidative Stress Are
Interrelated. Transplantation Proceedings 2006;38(4):1026-30.

82.

Ioannidou E, Kao D, Chang N, Burleson J, Dongari-Bagtzoglou A. Elevated
serum interleukin-6 (IL-6) in solid-organ transplant recipients is positively
associated with tissue destruction and IL-6 gene expression in the periodontium.
J Periodontol 2006;77(11):1871-8.

83.

Cainelli F, Vento S. Infections and solid organ transplant rejection: a cause-andeffect relationship? Lancet Infect Dis 2002;2(9):539-49.

84.

Waiser J, Budde K, Katalinic A, Kuerzdorfer M, Riess R, Neumayer HH.
Interleukin-6 expression after renal transplantation. Nephrol Dial Transplant
1997;12(4):753-9.

85.

Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The
Pathophysiologic Roles of Interleukin-6 in Human Disease. Ann Intern Med
1998;128(2):127-37.

86.

Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C. The
implication of obesity and central fat on markers of chronic inflammation: The
ATTICA study. Atherosclerosis 2005;183(2):308-15.

73

87.

Herder C, Schneitler S, Rathmann W, Haastert B, Schneitler H, Winkler H, et al.
Low-Grade Inflammation, Obesity, and Insulin Resistance in Adolescents. J Clin
Endocrinol Metab 2007;92(12):4569-74.

88.

Pickup JC. Inflammation and Activated Innate Immunity in the Pathogenesis of
Type 2 Diabetes. Diabetes Care 2004;27(3):813-23.

89.

Cecka JM. The OPTN/UNOS Renal Transplant Registry. Clin Transpl 2005:1-16.

90.

Matas AJ, Payne WD, Sutherland DE, Humar A, Gruessner RW, Kandaswamy R,
et al. 2,500 living donor kidney transplants: a single-center experience. Ann Surg
2001;234(2):149-64.

91.

Dennis MJ, Foster MC, Ryan JJ, Burden RP, Morgan AG, Blamey RW. The
increasing importance of chronic rejection as a cause of renal allograft failure.
Transpl Int 1989;2(4):214-7.

92.

Perez RV, Brown DJ, Katznelson SA, Dubin JA, Muller HG, Chang T, et al.
Pretransplant systemic inflammation and acute rejection after renal
transplantation. Transplantation 2000;69(5):869-74.

93.

Perez RV, Huang CQ, Johnson JR, Gallay BJ, Gandhi MM, McVicar JP, et al.
Pretransplantation soluble adhesion molecule expression predicts outcome after
living donor renal transplantation. Arch Surg 2003;138(10):1113-9; discussion
19-20.

94.

Fink JC, Onuigbo MA, Blahut SA, Christenson RH, Mann D, Bartlett ST, et al.
Pretransplant serum C-reactive protein and the risk of chronic allograft
nephropathy in renal transplant recipients: a pilot case-control study. Am J
Kidney Dis 2002;39(5):1096-101.

74

95.

Berber I, Yigit B, Isitmangil G, Tellioglu G, Ozgezer T, Gulle S, et al. Evaluation
of pretransplant serum cytokine levels in renal transplant recipients. Transplant
Proc 2008;40(1):92-3.

96.

Kornman KS, Crane A, Wang HY, di Giovine FS, Newman MG, Pirk FW, et al.
The interleukin-1 genotype as a severity factor in adult periodontal disease. J
Clin Periodontol 1997;24(1):72-7.

97.

Taubman MA, Valverde P, Han X, Kawai T. Immune response: the key to bone
resorption in periodontal disease. J Periodontol 2005;76(11 Suppl):2033-41.

98.

Tervonen T, Raunio T, Knuuttila M, Karttunen R. Polymorphisms in the CD14
and IL-6 genes associated with periodontal disease. J Clin Periodontol
2007;34(5):377-83.

99.

Huynh-Ba G, Lang NP, Tonetti MS, Salvi GE. The association of the composite
IL-1 genotype with periodontitis progression and/or treatment outcomes: a
systematic review. J Clin Periodontol 2007;34(4):305-17.

100.

Beck JD, Koch GG, Zambon JJ, Genco RJ, Tudor GE. Evaluation of oral bacteria
as risk indicators for periodontitis in older adults. J Periodontol 1992;63(2):93-9.

101.

Beck JD, Koch GG, Rozier RG, Tudor GE. Prevalence and risk indicators for
periodontal attachment loss in a population of older community-dwelling blacks
and whites. J Periodontol 1990;61(8):521-8.

102.

Wheeler TT, McArthur WP, Magnusson I, Marks RG, Smith J, Sarrett DC, et al.
Modeling the relationship between clinical, microbiologic, and immunologic
parameters and alveolar bone levels in an elderly population. J Periodontol
1994;65(1):68-78.

103.

Matthews JB, Wright HJ, Roberts A, Ling-Mountford N, Cooper PR, Chapple IL.
Neutrophil hyper-responsiveness in periodontitis. J Dent Res 2007;86(8):718-22.
75

104.

Fredriksson MI, Gustafsson AK, Bergstrom KG, Asman BE. Constitutionally
hyperreactive neutrophils in periodontitis. J Periodontol 2003;74(2):219-24.

105.

Taylor GW, Burt BA, Becker MP, Genco RJ, Shlossman M, Knowler WC, et al.
Severe periodontitis and risk for poor glycemic control in patients with noninsulin-dependent diabetes mellitus. J Periodontol 1996;67(10 Suppl):1085-93.

106.

Riche EL, Boggess KA, Lieff S, Murtha AP, Auten RL, Beck JD, et al. Periodontal
disease increases the risk of preterm delivery among preeclamptic women. Ann
Periodontol 2002;7(1):95-101.

107.

Ruma M, Boggess K, Moss K, Jared H, Murtha A, Beck J, et al. Maternal
periodontal disease, systemic inflammation, and risk for preeclampsia. Am J
Obstet Gynecol 2008;198(4):389 e1-5.

108.

Canakci V, Canakci CF, Yildirim A, Ingec M, Eltas A, Erturk A. Periodontal
disease increases the risk of severe pre-eclampsia among pregnant women. J
Clin Periodontol 2007;34(8):639-45.

109.

D'Aiuto F, Ready D, Tonetti MS. Periodontal disease and C-reactive proteinassociated cardiovascular risk. J Periodontal Res 2004;39(4):236-41.

110.

Howell TH, Ridker PM, Ajani UA, Hennekens CH, Christen WG. Periodontal
disease and risk of subsequent cardiovascular disease in U.S. male physicians. J
Am Coll Cardiol 2001;37(2):445-50.

111.

Jones JA, Miller DR, Wehler CJ, Rich SE, Krall-Kaye EA, McCoy LC, et al. Does
periodontal care improve glycemic control? The Department of Veterans Affairs
Dental Diabetes Study. J Clin Periodontol 2007;34(1):46-52.

112.

Michalowicz BS, Hodges JS, DiAngelis AJ, Lupo VR, Novak MJ, Ferguson JE, et
al. Treatment of periodontal disease and the risk of preterm birth. N Engl J Med
2006;355(18):1885-94.
76

113.

Manau C, Echeverria A, Agueda A, Guerrero A, Echeverria JJ. Periodontal
disease definition may determine the association between periodontitis and
pregnancy outcomes. J Clin Periodontol 2008;35(5):385-97.

114.

Levey A, Greene T, Kusek J, Beck G, Group M. A simplified equation to predict
glomerular filtration rate from serum creatinine [Abstract]. J Am Soc
Nephrol;11(A0828, 2000).

115.

Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP.
Post-transplant renal function in the first year predicts long-term kidney transplant
survival. Kidney Int 2002;62(1):311-8.

116.

Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum
creatinine. Nephron 1976;16(1):31-41.

117.

Poge U, Gerhardt T, Palmedo H, Klehr HU, Sauerbruch T, Woitas RP. MDRD
equations for estimation of GFR in renal transplant recipients. Am J Transplant
2005;5(6):1306-11.

118.

Morath C, Ritz E, Zeier M. Protocol biopsy: what is the rationale and what is the
evidence? Nephrol. Dial. Transplant. 2003;18(4):644-47.

119.

Shapiro R, Randhawa P, Jordan ML, Scantlebury VP, Vivas C, Jain A, et al. An
analysis of early renal transplant protocol biopsies--the high incidence of
subclinical tubulitis. Am J Transplant 2001;1(1):47-50.

120.

Rush D, Nickerson P, Gough J, McKenna R, Grimm P, Cheang M, et al.
Beneficial effects of treatment of early subclinical rejection: a randomized study.
J Am Soc Nephrol 1998;9(11):2129-34.

121.

Rush DN, Henry SF, Jeffery JR, Schroeder TJ, Gough J. Histological findings in
early routine biopsies of stable renal allograft recipients. Transplantation
1994;57(2):208-11.
77

122.

Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute
rejection episode on long-term renal allograft survival (t1/2). Transplantation
1994;57(6):857-9.

123.

McKenna RM, Lee KR, Gough JC, Jeffery JR, Grimm PC, Rush DN, et al.
Matching for private or public HLA epitopes reduces acute rejection episodes and
improves two-year renal allograft function. Transplantation 1998;66(1):38-43.

124.

Shoskes DA, Cecka JM. Effect of delayed graft function on short- and long-term
kidney graft survival. Clin Transpl 1997:297-303.

125.

Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL. Chronic renal
allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int
1996;49(2):518-24.

126.

Suthanthiran M. The importance of genetic polymorphisms in renal
transplantation. Curr Opin Urol 2000;10(2):71-5.

127.

Krüger B, Schröppel B, Murphy BT. Genetic polymorphisms and the fate of the
transplanted organ. Transplantation Reviews 2008;22(2):131-40.

128.

Breulmann B, Bantis C, Siekierka M, Blume C, Aker S, Kuhr N, et al. Influence of
cytokine genes polymorphisms on long-term outcome in renal transplantation.
Clin Transplant 2007;21(5):615-21.

129.

Asderakis A, Sankaran D, Dyer P, Johnson RW, Pravica V, Sinnott PJ, et al.
Association of polymorphisms in the human interferon-gamma and interleukin-10
gene with acute and chronic kidney transplant outcome: the cytokine effect on
transplantation. Transplantation 2001;71(5):674-7.

130.

Hoffmann S, Park J, Jacobson LM, Muehrer RJ, Lorentzen D, Kleiner D, et al.
Donor genomics influence graft events: the effect of donor polymorphisms on
acute rejection and chronic allograft nephropathy. Kidney Int 2004;66(4):1686-93.
78

131.

Tinckam K, Rush D, Hutchinson I, Dembinski I, Pravica V, Jeffery J, et al. The
relative importance of cytokine gene polymorphisms in the development of early
and late acute rejection and six-month renal allograft pathology. Transplantation
2005;79(7):836-41.

132.

Pelletier R, Pravica V, Perrey C, Xia D, Ferguson RM, Hutchinson I, et al.
Evidence for a genetic predisposition towards acute rejection after kidney and
simultaneous kidney-pancreas transplantation. Transplantation 2000;70(4):67480.

133.

Alakulppi NS, Kyllonen LE, Jantti VT, Matinlauri IH, Partanen J, Salmela KT, et al.
Cytokine gene polymorphisms and risks of acute rejection and delayed graft
function after kidney transplantation. Transplantation 2004;78(10):1422-8.

134.

McLaren AJ, Marshall SE, Haldar NA, Mullighan CG, Fuggle SV, Morris PJ, et al.
Adhesion molecule polymorphisms in chronic renal allograft failure. Kidney Int
1999;55(5):1977-82.

135.

Abdi R, Tran TB, Sahagun-Ruiz A, Murphy PM, Brenner BM, Milford EL, et al.
Chemokine receptor polymorphism and risk of acute rejection in human renal
transplantation. J Am Soc Nephrol 2002;13(3):754-8.

136.

Cullinan MP, Westerman B, Hamlet SM, Palmer JE, Faddy MJ, Lang NP, et al. A
longitudinal study of interleukin-1 gene polymorphisms and periodontal disease
in a general adult population. J Clin Periodontol 2001;28(12):1137-44.

137.

Shimada Y, Tai H, Endo M, Kobayashi T, Akazawa K, Yamazaki K. Association
of tumor necrosis factor receptor type 2 +587 gene polymorphism with severe
chronic periodontitis. J Clin Periodontol 2004;31(6):463-9.

79

138.

Inagaki K, Krall EA, Fleet JC, Garcia RI. Vitamin D receptor alleles, periodontal
disease progression, and tooth loss in the VA dental longitudinal study. J
Periodontol 2003;74(2):161-7.

139.

Schroder NW, Meister D, Wolff V, Christan C, Kaner D, Haban V, et al. Chronic
periodontal disease is associated with single-nucleotide polymorphisms of the
human TLR-4 gene. Genes Immun 2005;6(5):448-51.

140.

Donati M, Berglundh T, Hytonen AM, Hahn-Zoric M, Hanson LA, Padyukov L.
Association of the -159 CD14 gene polymorphism and lack of association of the 308 TNFA and Q551R IL-4RA polymorphisms with severe chronic periodontitis in
Swedish Caucasians. J Clin Periodontol 2005;32(5):474-9.

141.

Heitz-Mayfield LJ. Disease progression: identification of high-risk groups and
individuals for periodontitis. J Clin Periodontol 2005;32 Suppl 6:196-209.

142.

Nikolopoulos GK, Dimou NL, Hamodrakas SJ, Bagos PG. Cytokine gene
polymorphisms in periodontal disease: a meta-analysis of 53 studies including
4178 cases and 4590 controls. J Clin Periodontol 2008;35(9):754-67.

143.

Gera M, Slezak JM, Rule AD, Larson TS, Stegall MD, Cosio FG. Assessment of
changes in kidney allograft function using creatinine-based estimates of
glomerular filtration rate. Am J Transplant 2007;7(4):880-7.

144.

Wigger M, Druckler E, Muscheites J, Stolpe HJ. Course of glomerular filtration
rate after renal transplantation and the influence of hypertension. Clin Nephrol
2001;56(6):S30-4.

145.

Muller-Steinhardt M, Hartel C, Muller B, Kirchner H, Fricke L. The interleukin-6 174promoter polymorphism is associated with long-term kidney allograft survival.
Kidney Int 2002;62(5):1824-7.

80

146.

Massy ZA, Guijarro C, Kasiske BL. Clinical predictors of chronic renal allograft
rejection. Kidney Int Suppl 1995;52:S85-8.

147.

Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P, et al. Risk
factors for chronic rejection in renal allograft recipients. Transplantation
1993;55(4):752-6; discussion 56-7.

81

